PE20040655A1 - Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen - Google Patents
Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienenInfo
- Publication number
- PE20040655A1 PE20040655A1 PE2003000688A PE2003000688A PE20040655A1 PE 20040655 A1 PE20040655 A1 PE 20040655A1 PE 2003000688 A PE2003000688 A PE 2003000688A PE 2003000688 A PE2003000688 A PE 2003000688A PE 20040655 A1 PE20040655 A1 PE 20040655A1
- Authority
- PE
- Peru
- Prior art keywords
- iloxi
- hydroximethyl
- pyran
- tetrahydro
- procedures
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R1 Y R2 SON HALOGENO, NO2, CN, COOH, ENTRE OTROS; A ES ALCANODIILO(C0-C15) OPCIONALMENTE SUSTITUIDO; n ES 0-4; Cyc1 ES UN ANILLO DE 3 A 7 MIEMBROS SATURADO O INSATURADO CON 1 HETEROATOMO OPCIONAL DE O O S; R3, R4 Y R5 SON H, HALOGENO, OH, NO2, ENTRE OTROS; O R3 Y R4, JUNTO A LOS ATOMOS DE CARBONO QUE DE SOPORTE, FORMAN UN ANILLO Cyc2 DE 5 A 7 MIEMBROS SATURADO O INSATURADO, CON UNO O 2 HETEROATOMOS OPCIONALES DE N, O, S. SON COMPUESTOS PREFERIDOS: 3-(4-METOXI-FENIL)-1-[3-(3,4,5-TRIHIDROXI-6-HIDROXIMETIL-TETRAHIDRO-PIRAN-2-ILOXI)-TIOFEN-2-IL]-PROPAN-1-ONA; 2-HIDROXIMETIL-6-[2-(4-METOXI-BENCIL)-TIOFEN-3-ILOXI]-TETRAHIDRO-PIRAN-3,4,5-TRIOL Y ACIDO 4-[3-(3,4,5-TRIHIDROXI-6-HIDROXIMETIL-TETRAHIDRO-PIRAN-2-ILOXI)-TIOFEN-2-ILMETIL]-BENZOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE LA DIABETES TIPO I Y TIPO II
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10231370A DE10231370B4 (de) | 2002-07-11 | 2002-07-11 | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040655A1 true PE20040655A1 (es) | 2004-11-15 |
Family
ID=30009905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000688A PE20040655A1 (es) | 2002-07-11 | 2003-07-09 | Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US7101856B2 (es) |
| EP (4) | EP1964844B1 (es) |
| JP (1) | JP4511927B2 (es) |
| KR (1) | KR20050021452A (es) |
| CN (2) | CN100384863C (es) |
| AR (1) | AR040474A1 (es) |
| AT (4) | ATE477266T1 (es) |
| AU (1) | AU2003246620B2 (es) |
| BR (1) | BR0312513A (es) |
| CA (1) | CA2493391C (es) |
| CR (1) | CR7718A (es) |
| CY (1) | CY1108754T1 (es) |
| DE (5) | DE10231370B4 (es) |
| DK (1) | DK1523488T3 (es) |
| EC (1) | ECSP055531A (es) |
| ES (1) | ES2316818T3 (es) |
| HN (1) | HN2003000215A (es) |
| HR (1) | HRP20050014A2 (es) |
| IL (2) | IL166058A0 (es) |
| JO (1) | JO2707B1 (es) |
| MA (1) | MA27366A1 (es) |
| ME (1) | MEP60708A (es) |
| MX (1) | MXPA05000044A (es) |
| MY (1) | MY137039A (es) |
| NO (1) | NO20050649L (es) |
| OA (1) | OA12880A (es) |
| PA (1) | PA8577101A1 (es) |
| PE (1) | PE20040655A1 (es) |
| PL (1) | PL372931A1 (es) |
| PT (1) | PT1523488E (es) |
| RS (1) | RS51002B (es) |
| RU (1) | RU2317300C2 (es) |
| SI (1) | SI1523488T1 (es) |
| TN (1) | TNSN05007A1 (es) |
| TW (1) | TWI318981B (es) |
| UA (1) | UA78823C2 (es) |
| UY (1) | UY27891A1 (es) |
| WO (1) | WO2004007517A1 (es) |
| ZA (1) | ZA200409779B (es) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN1761676A (zh) | 2003-04-01 | 2006-04-19 | 大正制药株式会社 | 杂芳基5－硫代－β－D－吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药 |
| DK1651658T4 (da) | 2003-08-01 | 2020-11-09 | Mitsubishi Tanabe Pharma Corp | Nye forbindelser med hæmmende aktivitet mod natriumafhængig transporter |
| US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| DE102004063099B4 (de) * | 2004-12-22 | 2009-02-12 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Thiophenglycosidderivaten |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| TWI365186B (en) | 2005-01-31 | 2012-06-01 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
| BRPI0609665A2 (pt) | 2005-03-23 | 2010-04-20 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
| US7951794B2 (en) * | 2005-06-24 | 2011-05-31 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives |
| PL1979345T3 (pl) | 2006-01-24 | 2010-04-30 | Actelion Pharmaceuticals Ltd | Nowe pochodne pirydyny |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| TWI418556B (zh) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| TWI432446B (zh) | 2006-07-27 | 2014-04-01 | Chugai Pharmaceutical Co Ltd | 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用 |
| TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
| JPWO2008044762A1 (ja) * | 2006-10-13 | 2010-02-18 | 中外製薬株式会社 | チオグルコーススピロケタール誘導体、およびその糖尿病治療薬としての使用 |
| AU2007329490B2 (en) | 2006-12-04 | 2012-05-17 | Janssen Pharmaceutica N.V. | Thienyl-containing glycopyranosyl derivatives as antidiabetics |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| KR101552187B1 (ko) | 2007-09-10 | 2015-09-10 | 얀센 파마슈티카 엔.브이. | Ｓｇｌｔ 억제제로서 유용한 화합물의 제조 방법 |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| WO2009138195A2 (en) * | 2008-05-16 | 2009-11-19 | Sanofi-Aventis Deutschland Gmbh | Use of thiophene glycoside derivatives for producing medicaments for treatment of hypertension |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| ES2380408T3 (es) * | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| UA102429C2 (ru) | 2009-02-13 | 2013-07-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| EA022186B1 (ru) | 2009-07-10 | 2015-11-30 | Янссен Фармацевтика Нв | СПОСОБ КРИСТАЛЛИЗАЦИИ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНИЛ)-2-ТИЕНИЛМЕТИЛ]БЕНЗОЛА |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| HRP20150945T1 (hr) | 2009-09-30 | 2015-10-09 | Boehringer Ingelheim International Gmbh | Postupci za proizvodnju derivata benzil-benzena supstituiranog glukopiranozilom |
| EA020798B1 (ru) | 2009-09-30 | 2015-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| UA109883C2 (uk) | 2009-10-14 | 2015-10-26 | Спосіб отримання сполук для застосування як інгібіторів sglt2 | |
| CN102510867A (zh) | 2009-10-20 | 2012-06-20 | 诺瓦提斯公司 | 糖苷衍生物及其用途 |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| WO2011051864A1 (en) | 2009-11-02 | 2011-05-05 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011120923A1 (en) | 2010-03-30 | 2011-10-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
| US20130023494A1 (en) | 2010-04-06 | 2013-01-24 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| HRP20161231T1 (hr) | 2010-05-11 | 2016-11-04 | Janssen Pharmaceutica N.V. | Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP2014505058A (ja) * | 2011-01-11 | 2014-02-27 | ザ・ユニバーシティ・オブ・テキサス・エム・ディー・アンダーソン・キャンサー | 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物 |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012140120A1 (en) | 2011-04-13 | 2012-10-18 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
| US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| CN103619862A (zh) | 2011-04-14 | 2014-03-05 | 诺瓦提斯公司 | 糖苷衍生物及其用途 |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| EP2714052B1 (en) | 2011-06-03 | 2018-09-19 | Boehringer Ingelheim International GmbH | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
| ES2740299T3 (es) | 2013-03-14 | 2020-02-05 | Msd Int Gmbh | Métodos para preparar inhibidores de SGLT2 |
| PL2981269T3 (pl) | 2013-04-04 | 2024-02-05 | Boehringer Ingelheim Vetmedica Gmbh | Leczenie zaburzeń metabolicznych u zwierząt koniowatych |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| JP6545660B2 (ja) | 2013-04-05 | 2019-07-17 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 抗増殖活性を有する２−デオキシ−単糖類のエステル |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303098A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| MX2021004308A (es) | 2013-04-18 | 2022-10-26 | Boehringer Ingelheim Int | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria. |
| LT3862003T (lt) | 2013-12-17 | 2023-12-27 | Boehringer Ingelheim Vetmedica Gmbh | Sglt-2 inhibitorius, skirtas naudoti taikant medžagų apykaitos sutrikimo gydymą kačių šeimos gyvūnams |
| RS64355B1 (sr) | 2014-01-23 | 2023-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Sglt2 inhibitori za lečenje metaboličkih poremećaja kod životinja iz roda kanin |
| NZ723781A (en) | 2014-04-01 | 2022-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
| EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
| HUE068152T2 (hu) | 2014-09-25 | 2024-12-28 | Boehringer Ingelheim Vetmedica Gmbh | SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben |
| CN104478966A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| CN104478968A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| CA3041169A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| KR20250097990A (ko) | 2016-11-10 | 2025-06-30 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| WO2019201752A1 (en) | 2018-04-17 | 2019-10-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| EA202191114A1 (ru) | 2018-10-29 | 2021-09-22 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные пиридинилсульфонамида, фармацевтические композиции и их применение |
| JP7425793B2 (ja) | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
| EP4064854A1 (en) | 2019-11-28 | 2022-10-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
| KR20220143732A (ko) | 2020-02-17 | 2022-10-25 | 베링거잉겔하임베트메디카게엠베하 | 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용 |
| US20240269105A1 (en) | 2021-07-28 | 2024-08-15 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| EP4376830A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
| AU2022319909A1 (en) | 2021-07-28 | 2024-02-22 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
| CN119997931A (zh) | 2021-12-30 | 2025-05-13 | 纽阿姆斯特丹制药公司 | Obicetrapib和SGLT2抑制剂组合 |
| EP4531810A1 (en) | 2022-05-25 | 2025-04-09 | Boehringer Ingelheim Vetmedica GmbH | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| KR20240109921A (ko) | 2023-01-05 | 2024-07-12 | 아주대학교산학협력단 | Gptc 제조방법 |
| US20240307628A1 (en) | 2023-03-06 | 2024-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
| WO2024226537A1 (en) | 2023-04-24 | 2024-10-31 | Newamsterdam Pharma B.V. | Amorphous obicetrapib and sglt2 inhibitor combination |
| AU2024277852A1 (en) | 2023-05-24 | 2025-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan |
| WO2024240632A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA165448A (en) | 1914-10-23 | 1915-10-12 | Otto F. Hornschuch | Ironing board |
| FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| WO1997026265A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| ATE246190T1 (de) | 1996-12-31 | 2003-08-15 | Reddys Lab Ltd Dr | Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten |
| DE19726167B4 (de) * | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| KR20010021936A (ko) | 1997-07-16 | 2001-03-15 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용 |
| CO4970713A1 (es) * | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
| GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| EP1177187B1 (en) | 1999-04-28 | 2007-07-25 | Sanofi-Aventis Deutschland GmbH | Di-aryl acid derivatives as ppar receptor ligands |
| PT1177176E (pt) | 1999-04-28 | 2006-08-31 | Aventis Pharma Gmbh | Derivados de acidos triarilicos como ligandos de receptores ppar. |
| AU4808300A (en) | 1999-04-30 | 2000-11-17 | Neurogen Corporation | 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands |
| GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
| EP1194146B1 (en) | 1999-06-18 | 2006-07-19 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
| WO2001009111A1 (en) | 1999-07-29 | 2001-02-08 | Eli Lilly And Company | Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
| US6324512B1 (en) * | 1999-08-26 | 2001-11-27 | Matsushita Electric Industrial Co., Ltd. | System and method for allowing family members to access TV contents and program media recorder over telephone or internet |
| KR100591585B1 (ko) * | 1999-08-31 | 2006-06-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체 |
| DK1277736T3 (da) | 2000-04-28 | 2007-10-01 | Asahi Kasei Pharma Corp | Hidtil ukendte bicykliske forbindelser |
| WO2001085695A1 (en) | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| AU2001264977B2 (en) | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
-
2002
- 2002-07-11 DE DE10231370A patent/DE10231370B4/de not_active Expired - Fee Related
-
2003
- 2003-06-23 JO JOP/2003/0068A patent/JO2707B1/ar active
- 2003-06-27 EP EP08008079A patent/EP1964844B1/de not_active Expired - Lifetime
- 2003-06-27 DE DE50312984T patent/DE50312984D1/de not_active Expired - Lifetime
- 2003-06-27 OA OA1200500001A patent/OA12880A/en unknown
- 2003-06-27 AT AT08008232T patent/ATE477266T1/de active
- 2003-06-27 AT AT03763662T patent/ATE414095T1/de not_active IP Right Cessation
- 2003-06-27 AT AT08009226T patent/ATE477265T1/de active
- 2003-06-27 KR KR10-2005-7000500A patent/KR20050021452A/ko not_active Ceased
- 2003-06-27 PL PL03372931A patent/PL372931A1/xx not_active Application Discontinuation
- 2003-06-27 AT AT08008079T patent/ATE479697T1/de active
- 2003-06-27 EP EP03763662A patent/EP1523488B1/de not_active Expired - Lifetime
- 2003-06-27 CA CA2493391A patent/CA2493391C/en not_active Expired - Fee Related
- 2003-06-27 ME MEP-607/08A patent/MEP60708A/xx unknown
- 2003-06-27 RU RU2005103602/04A patent/RU2317300C2/ru not_active IP Right Cessation
- 2003-06-27 UA UAA200501215A patent/UA78823C2/uk unknown
- 2003-06-27 JP JP2004520429A patent/JP4511927B2/ja not_active Expired - Fee Related
- 2003-06-27 PT PT03763662T patent/PT1523488E/pt unknown
- 2003-06-27 MX MXPA05000044A patent/MXPA05000044A/es active IP Right Grant
- 2003-06-27 CN CNB038165325A patent/CN100384863C/zh not_active Expired - Fee Related
- 2003-06-27 EP EP08008232A patent/EP1967523B1/de not_active Expired - Lifetime
- 2003-06-27 DK DK03763662T patent/DK1523488T3/da active
- 2003-06-27 EP EP08009226A patent/EP1964845B1/de not_active Expired - Lifetime
- 2003-06-27 CN CNA2008100828971A patent/CN101240000A/zh active Pending
- 2003-06-27 WO PCT/EP2003/006841 patent/WO2004007517A1/de not_active Ceased
- 2003-06-27 SI SI200331500T patent/SI1523488T1/sl unknown
- 2003-06-27 BR BR0312513-0A patent/BR0312513A/pt not_active IP Right Cessation
- 2003-06-27 DE DE50313056T patent/DE50313056D1/de not_active Expired - Lifetime
- 2003-06-27 DE DE50310783T patent/DE50310783D1/de not_active Expired - Lifetime
- 2003-06-27 DE DE50312983T patent/DE50312983D1/de not_active Expired - Lifetime
- 2003-06-27 AU AU2003246620A patent/AU2003246620B2/en not_active Ceased
- 2003-06-27 HR HR20050014A patent/HRP20050014A2/hr not_active Application Discontinuation
- 2003-06-27 RS YUP-1150/04A patent/RS51002B/sr unknown
- 2003-06-27 ES ES03763662T patent/ES2316818T3/es not_active Expired - Lifetime
- 2003-07-08 AR AR20030102456A patent/AR040474A1/es unknown
- 2003-07-09 TW TW092118657A patent/TWI318981B/zh active
- 2003-07-09 PE PE2003000688A patent/PE20040655A1/es not_active Application Discontinuation
- 2003-07-10 PA PA20038577101A patent/PA8577101A1/es unknown
- 2003-07-10 MY MYPI20032596A patent/MY137039A/en unknown
- 2003-07-10 HN HN2003000215A patent/HN2003000215A/es unknown
- 2003-07-11 US US10/616,945 patent/US7101856B2/en not_active Expired - Lifetime
- 2003-07-11 UY UY27891A patent/UY27891A1/es unknown
-
2004
- 2004-12-02 ZA ZA200409779A patent/ZA200409779B/en unknown
- 2004-12-14 MA MA28004A patent/MA27366A1/fr unknown
- 2004-12-23 IL IL16605804A patent/IL166058A0/xx not_active IP Right Cessation
-
2005
- 2005-01-10 TN TNP2005000007A patent/TNSN05007A1/en unknown
- 2005-01-11 EC EC2005005531A patent/ECSP055531A/es unknown
- 2005-02-07 NO NO20050649A patent/NO20050649L/no unknown
- 2005-03-07 CR CR7718A patent/CR7718A/es not_active Application Discontinuation
-
2006
- 2006-08-14 US US11/464,338 patent/US7666848B2/en not_active Expired - Fee Related
-
2008
- 2008-06-03 IL IL191926A patent/IL191926A0/en unknown
-
2009
- 2009-02-05 CY CY20091100138T patent/CY1108754T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040655A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen | |
| AR032624A1 (es) | Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica | |
| BR0213253A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia | |
| PE52299A1 (es) | Bencenosulfonamidas de tiazol como agonistas de b3 para el tratamiento de la diabetes y la obesidad | |
| PE20060949A1 (es) | Derivados fusionados de pirazol como agonistas del receptor de niacina | |
| RU2003121236A (ru) | Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием | |
| AR035631A1 (es) | Compuestos quimicos | |
| RU2008142600A (ru) | Органическое соединение | |
| AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
| RU2008142261A (ru) | Фармацевтическая композиция с модифицированным высвобождением и ее применение | |
| PE20040577A1 (es) | Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion y medicamentos que las comprenden | |
| ZA874812B (en) | Drug | |
| Adams et al. | Amphipathic 3-Phenyl-7-propylbenzisoxazoles; human pPaR γ, δ and α agonists | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| PE20011183A1 (es) | Metabolitos agonistas/antagonistas de estrogeno | |
| AR015466A1 (es) | Derivados de tetrahidropiridopirimidinona 3-sustituido y su uso | |
| AR065208A1 (es) | Derivados de tetrahidronaftaleno sustituidos con heterociclos o sus analogos bencilsustituidos, metodo de preparacion, medicamentos que los contienen y usos de los mismos, como ligandos de receptores 5-ht7, en patologias asociadas al snc, entre otras. | |
| MX9304403A (es) | Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol | |
| AR034557A1 (es) | Derivados de (2-azabiclo[2.2.1]hept-7-il)metanol como agonistas de receptores nicotinicos de acetilcolina | |
| AR035698A1 (es) | Derivados de guanidina biciclicos, procedimiento para preparar estos compuestos y composicion farmaceutica | |
| AR008245A1 (es) | Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados | |
| AR029259A1 (es) | Compuestos 1,1'(1,2 etendiilo) bis (benceno) sustituidos, un proceso para su preparacion composiciones farmaceuticas y el uso de dichos compuestos para preparar agentes intensificadores de la absorcion de glucosa | |
| PE20070827A1 (es) | DERIVADOS DE ISOQUINOLINA Y BENZO[h]ISOQUINOLINA, SU PREPARACION Y SU UTILIZACION EN TERAPEUTICA | |
| PT90706A (pt) | Processo para a preparacao de derivados de antraciclinas dotados de actividade citostatica | |
| AR036509A1 (es) | Nuevo uso de aminometil cromanos sustituidos para el tratamiento de los trastornos de movimiento y de los efectos adversos inducidos por farmacos administrados para tratar trastornos de movimientos extrapiramidales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |